CMS Will End Medicare Part D Premium Stabilization Program After 2026
The agency says drug plan insurers can now price without the extra federal payments; analysts and Democrats say some seniors will see bigger premium jumps in 2027.
The Rebate That Was Never Meant to Stay
For two years, roughly 25 million Medicare enrollees have been paying less for their drug plans than the math said they should[3][5]. A government demonstration program quietly picked up part of the tab. On July 28, 2026, the Centers for Medicare & Medicaid Services said that arrangement is over. The 2027 plan year will run without it[1][2].
Both sides agree on the basic shape of what happened. In 2025, under the Biden administration, CMS launched the Part D Premium Stabilization Demonstration. It cut what enrollees paid by up to $15 a month and capped how much any plan's premium could jump year to year, at $35[3]. Nearly every company selling stand-alone drug plans signed up[3]. CMS estimated the two-year cost at $9.8 billion[3]. The Congressional Budget Office put the three-year cost, had it continued, above $21 billion[14]. None of that is disputed. What's disputed is whether the program was rescuing a market or just delaying an inevitable bill — and who should pay it now.
A Number Both Camps Cite, and Both Read Differently
CMS Administrator Dr. Mehmet Oz posted on social media that "the Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies," calling the program a bailout[12]. He argues the payments propped up an industry, not seniors, and that ending them is simple fiscal cleanup once insurers no longer need the crutch[1][12]. CMS says its review of the bids insurers submitted for 2027 shows plans have adjusted to recent changes in the drug benefit, so the market can return to normal[1].
Senate Minority Leader Chuck Schumer called the decision "heartless, cruel, and completely by choice"[5]. KFF, a health policy research nonprofit, estimates the subsidy cut the average stand-alone plan premium by about $16 this year, against an average premium near $36[5]. That's close to a third of the bill, for people often living on fixed incomes. KFF's Juliette Cubanski warned some enrollees "could face relatively steep premium increases" in 2027[4][5].
Here's the tension: both figures come from the same government record, and both sides quote it selectively. The Government Accountability Office's February 2026 report confirmed the $9.8 billion cost and the near-universal insurer participation[3]. But it also said something both camps tend to skip — no completed evaluation yet shows how much of the recent premium stability the demonstration actually caused, versus other factors[3]. Nobody can currently prove the subsidy was either a necessary lifeline or an unnecessary handout. That gap is where the argument actually lives.
Why Insurers Say the Ground Shifted Under Them
To understand why insurers wanted the money at all, it helps to know what changed underneath Part D. The Inflation Reduction Act capped how much an enrollee has to pay out of pocket for drugs each year. Once a patient hits that cap, the insurer picks up nearly all the remaining cost[13][18]. That's a real benefit for patients with expensive prescriptions. But it also means a single very sick enrollee can now blow a hole in a plan's budget in a way that wasn't possible before.
The law also narrowed what are called risk corridors — a mechanism where the government shares some of the loss with an insurer when a plan's costs come in higher than expected[13]. Smaller corridors mean insurers absorb more of a bad year themselves. The stabilization demonstration was built to offset exactly that new exposure, holding enrollee premiums down while the government helped cover the risk[3][13].
Take the demonstration away, and insurers say the risk doesn't disappear — it just has nowhere left to go but the premium. The industry's main lobbying group, AHIP, said only that it was still assessing the announcement[15]. That caution likely reflects a genuine bind: being cast as bailout recipients and being cast as premium-hikers are both bad optics, whichever the company ends up being. The market's shrinking regardless. The average Medicare enrollee could pick from just 14 stand-alone drug plans in 2026, the fewest since Part D began in 2006[18].
What $41.33 Actually Means, and What It Doesn't
CMS set the 2027 national base beneficiary premium at $41.33, up from $38.99 — a $2.34 increase, and the maximum allowed under a separate Inflation Reduction Act cap limiting yearly growth to 6% through 2029[1][5]. That figure gets quoted constantly, but it's worth being precise about what it is. It's a government benchmark used to calculate other numbers in the system, not a bill anyone actually receives. Real, plan-by-plan premiums for 2027 won't be published until September, weeks before open enrollment starts in October[5].
So for now, no one — not CMS, not insurers, not the roughly 25 million people who buy stand-alone drug coverage — actually knows what individual premiums will look like[3][5]. CMS's own estimate holds that about 25% of enrollees will see flat or lower premiums, and roughly 30% will pay under $10 more a month[7]. That leaves a meaningful share facing larger increases, and it's impossible to say in advance who.
The uncertainty cuts differently depending on who you are. People with high drug costs have generally gained the most from the new out-of-pocket cap, and now face the premium side of that same trade-off. People who rarely fill prescriptions have been paying for coverage they barely use, and some may find cheaper options once 2027 plans are final.
An Argument With an Election-Shaped Shadow
The timing hasn't escaped notice on either side. The demonstration launched in July 2024, months before a presidential election. It's ending in July 2026, months before a midterm[8][9]. Right-leaning outlets have tended to present the 2024 launch date as evidence of political motive behind the original program[8]. Democrats and groups like the Democratic National Committee, whose spokesperson Kendall Witmer said Republicans "are doing everything they can to make health care unaffordable for Americans, especially for seniors," argue the timing of the rollback is itself the political choice[5].
Both readings can be true at once, since both dates are simply facts. Coverage split along familiar lines: Fox News led with a neutral "will end" framing that avoided assigning blame[11], while The Epoch Times foregrounded the taxpayer cost and the pre-election launch[8]. NPR and STAT led instead with the risk to consumers and the political opening it hands Democrats[5][9]. Healthcare Dive, writing for an industry audience, focused mainly on bid mechanics and market exits[7]. Searches turned up no substantial coverage from major non-Western outlets — this is a domestic benefits-administration story without a foreign-policy angle, and its absence abroad is itself notable rather than a gap to fill in.
The Math That Doesn't Go Away
Strip away the framing, and one thing holds regardless of who's right about intent. Drug spending keeps rising. The out-of-pocket cap keeps the biggest costs with insurers. And the number of stand-alone drug plans keeps shrinking, a trend that started before this decision[18]. Something has to absorb that pressure — premiums, plan choices, or both.
A federal subsidy can shift who pays: taxpayers instead of enrollees, or vice versa. It can't make the underlying cost vanish. That's the reality CMS, insurers, and Congress will all still be negotiating over when the actual 2027 premiums land in September — and when the people paying them find out, for the first time, what the end of the subsidy means for their own bill[5].
Summary
On July 28, 2026, the Centers for Medicare & Medicaid Services said it will not continue the Medicare Part D Premium Stabilization Demonstration in 2027[1][2]. The program is a temporary federal payment to companies that sell stand-alone Medicare prescription drug plans. It started in 2025 under the Biden administration. In exchange for the money, insurers agreed to hold down what enrollees pay each month. CMS said it reviewed the 2027 bids insurers submitted and concluded plans have adjusted to recent changes in the drug benefit. So, the agency said, the program can return to "traditional market conditions"[1].
About 25 million people were in stand-alone drug plans in 2026 — roughly 42% of everyone with Part D coverage[3][5]. These are people on original Medicare who buy drug coverage separately. Most of the rest get drugs bundled into a Medicare Advantage plan and are not directly touched by this change. CMS set the 2027 national base beneficiary premium at $41.33, up from $38.99 in 2026[1]. That is the government's benchmark figure, not what anyone actually pays. Real premiums vary by plan, and CMS will not publish them until September[5].
The two sides disagree about what this money was. CMS Administrator Dr. Mehmet Oz called it a "bailout" and said billions went straight to insurance companies[12]. The Government Accountability Office reported that CMS estimated the demonstration would cost $9.8 billion across 2025 and 2026, and that nearly all plan sponsors signed up[3]. Congressional Budget Office analysts put the three-year cost above $21 billion if it had continued[14]. Senate Minority Leader Chuck Schumer called ending it "heartless, cruel, and completely by choice"[5]. KFF, a health policy research group, estimates the subsidy cut the average stand-alone plan premium by about $16 this year, against an average premium of roughly $36[5].
The real point of dispute is causation and necessity. CMS says the 2027 bids themselves show insurers no longer need the help. Critics say nobody can know that yet, and that the bill lands on seniors in an election year. GAO noted in February 2026 that a formal evaluation of the demonstration had not been completed — so how much of the premium stability the program actually caused, versus other changes to the drug benefit, remains unmeasured[3].
The Event
On July 28, 2026, CMS released its 2027 Part D bid information and its annual Parts C and D announcement[1][2]. In those documents the agency said the Part D Premium Stabilization Demonstration will end after the 2026 plan year and will not operate in 2027[1]. CMS set the 2027 national average monthly bid amount at $296.05 and the national base beneficiary premium at $41.33[1]. CMS Administrator Dr. Mehmet Oz posted on X that "We are stabilizing the market so this bailout is no longer needed"[12]. Final plan-by-plan 2027 premiums are scheduled for release in September 2026[5].
Undisputed Facts
- The Part D Premium Stabilization Demonstration began in plan year 2025 under the Biden administration and was voluntary for stand-alone drug plan sponsors[3][13].
- Under the demonstration, CMS cut enrollee premiums by up to $15 a month in 2025 and capped each plan's year-over-year premium increase at $35[3].
- GAO reported that CMS officials estimated the demonstration would cost $9.8 billion across 2025 and 2026, and that nearly all plan sponsors chose to take part[3].
- About 25 million people were enrolled in stand-alone Part D drug plans in 2026, about 42% of all Part D enrollees[3][5].
- CMS set the 2027 national base beneficiary premium at $41.33, up from $38.99 in 2026[1].
- A provision of the Inflation Reduction Act limits annual growth in the base beneficiary premium to no more than 6% through 2029[5].
- The average person on original Medicare could choose from 14 stand-alone drug plans in 2026 — the fewest since Part D began in 2006[18].
- As of its February 26, 2026 report, GAO said a completed evaluation separating the demonstration's effects from other Part D changes was not yet available[3].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- The IRA moved risk onto insurers
- The Inflation Reduction Act capped what a Part D enrollee pays out of pocket each year and pushed much of the cost above that cap onto plans. That is the root cause of premium instability. The demonstration papered over it; ending the demonstration does not undo it[13][18].
- Stand-alone drug plans are a shrinking business
- Medicare Advantage now dominates, and drug-only plans are left with an older, sicker, more expensive risk pool. Plan counts fell to 14 per beneficiary in 2026, the lowest since 2006 — a trend that began before this decision[18].
- The fiscal record is genuinely large
- CMS estimated $9.8 billion over two years; CBO projected more than $21 billion over three if continued[3][14]. Any administration would face pressure to end an open-ended demonstration of that size, whatever its politics.
- The election calendar
- The demonstration launched in July 2024, before a presidential election. It ends in July 2026, before a midterm. Both timings are facts; both sides read motive into the other's[8][9].
Material realityAbout 25 million people buy stand-alone Medicare drug coverage[3]. Their monthly premiums for 2027 are not yet known and will not be published until September 2026[5]. What is known is the government benchmark: $41.33 for 2027, up from $38.99[1]. That is a $2.34 increase in the reference number, but individual plans can and do price far above or below it. Independent of who wins the argument, the underlying math holds — drug spending keeps rising, the out-of-pocket cap keeps the liability with insurers, and the number of drug-only plans keeps falling. Premiums, plan choices, or both must absorb that. A federal subsidy could move the burden between taxpayers and enrollees. It could not make it disappear.
Narrative as a weaponThree actors are shaping how this reads. CMS and Administrator Oz want you to hear 'bailout' — money that went to insurance companies, not to seniors — so that ending it sounds like fiscal hygiene rather than a cut. Democrats and senior advocacy groups want you to hear the $16 a month coming off a $36 average premium, so that it sounds like a bill arriving in your mailbox. Insurers, who have said little publicly, want neither frame to stick: being cast as bailout recipients or as premium-hikers both hurt, so AHIP's response was that it is 'still assessing'[15]. The most quoted independent voice is KFF, which is a foundation-funded research group, not a neutral referee, and whose institutional interest leans toward preserving coverage subsidies. The one document both camps cite and both truncate is GAO's February 2026 report, which says the program's actual effect had not yet been measured — a finding that undercuts CMS's confidence that plans are ready and critics' confidence that the subsidy is what held premiums down[3].
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asCMS argues the payments were emergency scaffolding, not a permanent benefit, and scaffolding gets taken down when the building stands. The agency says it looked at what insurers actually bid for 2027 — the price each company says it needs to cover a year of drug claims — and concluded plans have absorbed the Inflation Reduction Act's redesign[1]. Administrator Oz frames the deeper principle as who the money went to: the checks were written to insurance companies, not to seniors, and a program that pays carriers to post lower sticker prices hides the true cost rather than lowering it[12]. Officials also argue the pain is smaller than critics suggest: an administration estimate holds that about 25% of enrollees will see flat or lower premiums and roughly 30% will pay under $10 more a month[7].
WhyThe administration wants to cut federal spending it did not create, and to hang the cost on its predecessor. Ending a program launched in July 2024 also lets it argue the original design was election-timed[8][14].
Impact on themIt removes an estimated $3.6 billion in 2026-scale outlays from future budgets[7]. The political exposure is real: premium notices land in the fall of 2026, weeks before midterm voting[9].
Frames it asThey argue that a subsidy people are already living on is not a windfall — removing it is a cost increase, whatever you call the program. Their central evidence is scale: KFF estimates the demonstration cut the average stand-alone premium by about $16 a month this year, against an average premium near $36[5]. Take away $16 from a $36 bill and the increase is close to 50%, not a rounding error, for people on fixed incomes. They also argue the timing is a choice, not a necessity — Schumer called it "heartless, cruel, and completely by choice"[5]. The Democratic National Committee's Kendall Witmer said Trump and Republicans "are doing everything they can to make health care unaffordable for Americans, especially for seniors"[5]. On the merits, they lean on GAO's finding that no completed evaluation exists — so CMS cannot show the market is ready[3].
WhyOut-of-pocket health costs are a durable Democratic advantage. A premium increase with a named federal decision behind it gives them a concrete midterm message[9].
Impact on themTheir voters overlap heavily with the 25 million people in stand-alone plans[3]. They gain an issue but hold no lever to reverse the decision without legislation.
Frames it asInsurers' strongest argument is structural, and it needs the mechanism to make sense. The Inflation Reduction Act capped what an enrollee pays out of pocket each year and moved much of the liability above that cap onto the plan. That made stand-alone drug plans far riskier to price, because a few very expensive patients can now blow up a plan's math. The demonstration also narrowed "risk corridors" — the band inside which the government shares unexpected losses with the plan[13]. Take the corridors back out and insurers say they must build that risk back into the premium. Carriers argue this is not greed: if the price does not cover the risk, the rational move is to leave the market, and the record shows exits are already happening — 14 plan choices in 2026, the fewest ever[18]. AHIP, the industry's main lobby, said it was still assessing the announcement[15].
WhyProtect margins on a line of business that has become structurally unprofitable, and avoid being the visible cause of a premium spike.
Impact on themPlans lose an estimated $3.6 billion in 2026-level support[7]. Some will raise premiums, some will thin their networks or formularies, and some will exit counties entirely.
Frames it asThis group is not organized around one argument, and its members split. People with high drug costs generally gained the most from the IRA's out-of-pocket cap and now face the premium side of that trade. People with few prescriptions have been paying premiums for coverage they barely use, and some of them may find cheaper plans in 2027. What unites them is a practical complaint: they cannot plan. CMS will not publish actual 2027 plan premiums until September, and open enrollment starts in October[5].
WhyPredictable monthly costs on a fixed income, and keeping access to the specific drugs and pharmacies they already use.
Impact on themEffects are highly uneven by plan and county. CMS's benchmark premium rises $2.34, from $38.99 to $41.33[1], but that figure is not a bill — an individual's actual increase depends on their plan's bid and could be far larger or smaller.
Like this article?
The Bias Ledger average rating 3.9
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| Healthcare Dive | U.S. center, industry trade publication serving health executives | 2 | "CMS to end subsidies for Medicare drug plan premiums" — flat, agency-as-subject, focused on market effects. | Written for insurers, so it emphasizes bid mechanics and market exits and gives comparatively little space to what beneficiaries will pay. |
| Fox News | U.S. right | 3 | "Medicare Part D subsidy program will end in 2027: Here's what to know" — service-journalism framing that avoids assigning blame and stresses that effects vary by plan. | Neutral verb choice ('will end', not 'cut') and an early note that some enrollees may pay less. The Biden origin of the program appears; the $16 average premium reduction does not lead. |
| KFF | U.S. health policy research nonprofit, foundation-endowed, generally supportive of coverage expansion | 3 | "CMS's Decision to End Temporary Subsidies... Could Mean Larger Premium Increases for Some Beneficiaries Next Year" — careful hedging in the headline itself. | Hedges precisely ('could', 'some'), which is honest. But it frames the story around downside risk to enrollees and not around the $9.8 billion cost, revealing which question it thinks matters. |
| NPR | U.S. center-left, partly federally chartered public media | 4 | "The Trump administration's move to end subsidies for Medicare drug plans could cost consumers" — the consumer cost is in the headline. | 'Could cost consumers' puts the harm first and the fiscal argument second. The $9.8 billion price tag and the administration's under-$10-a-month estimate appear late or briefly. |
| STAT | U.S. center, health-industry trade press owned by Boston Globe Media | 4 | "End of Medicare drug subsidy gives Democrats new attack line on rising out-of-pocket costs" — frames the decision mainly as a political opportunity. | Treats the policy as campaign material rather than benefit design. That is candid about incentives, but it sidelines whether the subsidy was working. |
| Newsweek | U.S. center, traffic-driven digital | 5 | "Trump Scraps Medicare Part D Subsidy: What It Means for Seniors" — personalizes the decision to Trump. | 'Scraps' is a harder verb than CMS's own 'will not continue'. Naming Trump rather than CMS shifts an agency bid review into a presidential act. |
| The Epoch Times | U.S. right, founded by practitioners of Falun Gong, strongly pro-Trump editorial line | 6 | "Trump Administration to End Medicare Drug Plan Subsidies" — foregrounds taxpayer cost and the pre-2024-election launch date. | Leads with the cost to taxpayers and Republican criticism of cost-shifting; the ~$16 monthly effect on enrollees is downstream or absent. |
References
- Medicare Part D 2027 National Average Monthly Bid Amount Information — Centers for Medicare & Medicaid Services · U.S. federal agency; primary source; issued under the Trump administration
- July 28, 2026 Announcement of Calendar Year 2027 Medicare Advantage and Part D Payment Policies — Centers for Medicare & Medicaid Services · U.S. federal agency; primary source document
- Medicare Part D: Implementation of Beneficiary Premium Stabilization Demonstration (GAO-26-107935) — U.S. Government Accountability Office · Nonpartisan congressional audit agency; reports to Congress, not the executive branch
- CMS's Decision to End Temporary Subsidies to Medicare's Stand-Alone Drug Plans Could Mean Larger Premium Increases for Some Beneficiaries Next Year — KFF · Foundation-endowed U.S. health policy nonprofit; generally favorable to coverage subsidies
- The Trump administration's move to end subsidies for Medicare drug plans could cost consumers — NPR · U.S. center-left public radio; mix of federal, member-station and donor funding
- Trump administration moves to end Biden-era Medicare Part D subsidy program — The Hill · U.S. center; Capitol Hill trade coverage owned by Nexstar
- CMS to end subsidies for Medicare drug plan premiums — Healthcare Dive · U.S. center; industry trade press for healthcare executives (Industry Dive)
- Trump Administration to End Medicare Drug Plan Subsidies — The Epoch Times · U.S. right; founded by Falun Gong practitioners, strongly pro-Trump editorial line
- End of Medicare drug subsidy gives Democrats new attack line on rising out-of-pocket costs — STAT · U.S. center; health and biotech trade outlet owned by Boston Globe Media
- Trump Scraps Medicare Part D Subsidy: What It Means for Seniors — Newsweek · U.S. center; traffic-driven digital news
- Medicare Part D subsidy program will end in 2027: Here's what to know — Fox News · U.S. right; Fox Corporation owned-and-operated station coverage
- Trump Administration Pulls the Plug on a Medicare Subsidy That Cut Drug Premiums — Oz Says the 'Bailout' Is No Longer Needed — Benzinga · U.S. financial-markets news; investor-focused, aggregation-heavy
- Medicare Part D Premium Stabilization Demonstration (IF12889) — Congressional Research Service · Nonpartisan research arm of the U.S. Congress
- CBO Confirms: Biden-Harris Medicare Cost-Shifting Policy Will Cost Taxpayers Billions — U.S. Senate Committee on the Budget · Republican committee staff press release; partisan framing of CBO figures
- CMS to end Medicare subsidies for drug plans — Healthcare Finance News · U.S. center; healthcare business trade publication (HIMSS Media)
- CMS to end Medicare Part D stabilization program — Becker's Hospital Review · U.S. center; hospital and pharmacy industry trade press
- 2027 NAMBA Signals Continued Market Pressures in Part D — Avalere Health · For-profit healthcare consultancy; clients include drugmakers and insurers
- The Uncertain Future of Medicare's Stand-Alone Prescription Drug Plan Market and Why It Matters — KFF · Foundation-endowed U.S. health policy nonprofit; generally favorable to coverage subsidies